Sanofi's Riliprubart Secures U.S. Orphan Drug Status For Solid Organ Transplant Rejection
25/6 07:39
(RTTNews) - The U.S. Food and Drug Administration has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation, Sanofi Winthrop Industrie said in a statement....